GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Net Income (Continuing Operations)

Karolinska Development AB (Karolinska Development AB) Net Income (Continuing Operations) : $3.08 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Karolinska Development AB Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Karolinska Development AB's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was $0.02 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was $3.08 Mil.


Karolinska Development AB Net Income (Continuing Operations) Historical Data

The historical data trend for Karolinska Development AB's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB Net Income (Continuing Operations) Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.12 -24.81 18.79 -8.49 0.53

Karolinska Development AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.67 2.16 1.08 -0.18 0.02

Karolinska Development AB Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Karolinska Development AB  (OTCPK:KDEVF) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Karolinska Development AB Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Karolinska Development AB (Karolinska Development AB) Business Description

Traded in Other Exchanges
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.